2. Search Result
Search Result
Results for "

blood insulin

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

5

Peptides

11

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103433
    K579

    		Dipeptidyl Peptidase Metabolic Disease
    K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic .
    K579
  • HY-109556
    Insulin Detemir

    		Akt ERK Metabolic Disease
    Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .
    Insulin Detemir
  • HY-N0936
    Coixol
    1 Publications Verification

    6-Methoxy-2-benzoxazolinone; 6-MBOA

    		 Others Inflammation/Immunology
    Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .
    Coixol
  • HY-W010031
    1-Methyluric acid

    		Endogenous Metabolite Metabolic Disease
    1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.
    1-Methyluric acid
  • HY-121565
    SaRI 59-801

    		Others Metabolic Disease Endocrinology
    SaRI 59-801 is an orally effective hypoglycemic compound. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice .
    SaRI 59-801
  • HY-117172
    CP320626

    		Others Metabolic Disease
    CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC50=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes .
    CP320626
  • HY-N12353
    Stevisalioside A

    		Phosphatase Metabolic Disease
    Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC50: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .
    Stevisalioside A
  • HY-123171
    ASP8497

    		Others Metabolic Disease
    ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .
    ASP8497
  • HY-P10337
    OXM-7

    		GCGR GLP Receptor Metabolic Disease Endocrinology
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
    OXM-7
  • HY-121796
    Mixanpril

    		Others Others
    Mixanpril is a compound with the ability to modulate insulin sensitivity and has the activity of regulating insulin sensitivity and femoral blood flow in obese Zucker rats. Mixanpril can affect insulin-mediated glucose disposal in obese Zucker rats and also has a regulatory effect on femoral blood flow, with different effects compared to the ACE inhibitor captopril.
    Mixanpril
  • HY-101637
    Reglitazar

    JT 501

    		 PPAR Metabolic Disease
    Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .
    Reglitazar
  • HY-117446
    AS-1669058

    		GPR119 Metabolic Disease
    AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .
    AS-1669058
  • HY-117446A
    AS-1669058 free base

    		GPR119 Metabolic Disease
    AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.
    AS-1669058 free base
  • HY-163652
    Glicetanile

    		Others Metabolic Disease
    Glicetanile is an orally active hypoglycemic agent, that stimulates the release of insulin from pancreatic beta cells, and lowers the blood sugar. Glicetanile exhibits potential in ameliorating the type 2 diabetes .
    Glicetanile
  • HY-N2118
    Bilobetin
    1 Publications Verification

    		 PPAR PKA Akt p38 MAPK ERK Metabolic Disease
    Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
    Bilobetin
  • HY-N13205
    Mulberry Extract

    		Others Metabolic Disease
    Mulberry Extract is a mulberry extract, and its components include: Anthocyanidins. Mulberry Extract regulates sugar and lipid metabolism, lowers blood sugar and increases insulin secretion. Its blood sugar regulating effect may be attributed to the phytochemicals it contains, mainly 1-deoxynojirimycin, flavonoids, phenolic compounds and polysaccharides. .
    Mulberry Extract
  • HY-164040
    Zavolosotine

    		Somatostatin Receptor Metabolic Disease
    Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC50 <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .
    Zavolosotine
  • HY-101116
    GLP-1R Antagonist 1
    2 Publications Verification

    		 GCGR Metabolic Disease
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
    GLP-1R Antagonist 1
  • HY-122120
    Rafabegron

    AJ‐9677

    		 Adrenergic Receptor Metabolic Disease
    Rafabegron (AJ-9677) is a specific beta3-adrenoceptor agonist. Rafabegron can reduce blood glucose, insulin, FFA, and triglyceride levels in diabetic and obese mouse models .
    Rafabegron
  • HY-109018A
    Velagliflozin proline
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline
  • HY-B0627A
    Metformin (glycinate)

    1,1-Dimethylbiguanide (glycinate)

    		 AMPK Autophagy Mitophagy Cardiovascular Disease Metabolic Disease Cancer
    Metformin glycinate inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin glycinate can cross the blood-brain barrier and triggers autophagy .
    Metformin (glycinate)
  • HY-N2118R
    Bilobetin (Standard)

    		PPAR PKA Akt p38 MAPK ERK Metabolic Disease
    Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
    Bilobetin (Standard)
  • HY-B0627
    Metformin
    Maximum Cited Publications
    121 Publications Verification

    1,1-Dimethylbiguanide

    		 AMPK Autophagy Mitophagy Cardiovascular Disease Metabolic Disease Cancer
    Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin can cross the blood-brain barrier and triggers autophagy .
    Metformin
  • HY-W010031S1
    1-Methyluric acid-d3

    		Isotope-Labeled Compounds Metabolic Disease
    1-Methyluric acid-d3 is the deuterium labeled 1-Methyluric acid (HY-W010031). 1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels .
    1-Methyluric acid-d3
  • HY-W145497
    D-(+)-Sorbose

    		Insulin Receptor Metabolic Disease
    D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus .
    D-(+)-Sorbose
  • HY-109018B
    Velagliflozin proline hydrate
    1 Publications Verification

    		 SGLT Metabolic Disease
    Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
    Velagliflozin proline hydrate
  • HY-159496
    Dyrk1A-IN-10

    		DYRK Metabolic Disease
    Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .
    Dyrk1A-IN-10
  • HY-117459
    E-3030 free acid

    		Others Metabolic Disease
    E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
    E-3030 free acid
  • HY-125088
    Oleoylestrone

    		Others Others
    Oleoyl-estrone (OE) is a signaling molecule derived from adipose tissue that reduces energy intake and body fat while maintaining energy expenditure and blood glucose balance. In studies in adrenalodepleted female rats, administration of OE resulted in significant fat mobilization, reduced food intake, and sustained energy expenditure. However, concomitant administration of corticosterone inhibits OE-induced fat mobilization and aggravates insulin resistance and glycemic imbalance by promoting fat deposition. This suggests that corticosterone has an antagonistic effect on the beneficial metabolic effects of OE, particularly on lipid metabolism and insulin sensitivity .
    Oleoylestrone
  • HY-129297
    CMPF

    		Endogenous Metabolite Metabolic Disease
    CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .
    CMPF
  • HY-W709961
    5-OAHSA

    1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .
    5-OAHSA
  • HY-118113
    BVT-116429

    		Others Others
    BVT-116429 is an 11βHSD1 inhibitor with the activity of increasing adiponectin concentration and improving glucose homeostasis in diabetic mice. BVT-116429 can increase plasma adiponectin levels in diabetic KKAy mice, reduce basal insulin levels, and reduce fasting blood glucose levels after 10 days of inhibition, similar to the effect of rosiglitazone.
    BVT-116429
  • HY-P10302
    GLP-1R/GIPR agonist-1

    		GLP Receptor Insulin Receptor Metabolic Disease
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1
  • HY-131334
    AMPK activator 4

    		AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
    AMPK activator 4
  • HY-14860
    1-Deoxynojirimycin
    3 Publications Verification

    Duvoglustat

    		 Glucosidase PI3K Metabolic Disease
    1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin
  • HY-14860A
    1-Deoxynojirimycin hydrochloride
    3 Publications Verification

    Duvoglustat hydrochloride

    		 Glucosidase PI3K Bacterial Antibiotic Infection Metabolic Disease
    1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin hydrochloride
  • HY-117985A
    Evogliptin hydrochloride

    DA-1229 hydrochloride

    		 Dipeptidyl Peptidase Metabolic Disease Endocrinology
    Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin hydrochloride
  • HY-14860R
    1-Deoxynojirimycin (Standard)

    		Glucosidase PI3K Metabolic Disease
    1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin (Standard)
  • HY-109692
    GPR120 Agonist 5

    		Free Fatty Acid Receptor Metabolic Disease Inflammation/Immunology
    GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC50=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases .
    GPR120 Agonist 5
  • HY-18555
    TMPA
    2 Publications Verification

    		 Nuclear Hormone Receptor 4A/NR4A AMPK Metabolic Disease Inflammation/Immunology Cancer
    TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation .
    TMPA
  • HY-B1245
    Salsalate
    2 Publications Verification

    Salicylsalicylic acid; Disalicylic acid

    		 Reactive Oxygen Species Inflammation/Immunology Cancer
    Salsalate is a potent antirheumatic drug with oral activity that reduces irritation during gastric absorption and avoids direct inhibition of cyclooxygenase. Salsalate not only has significant anti-inflammatory effects, but also reduces blood sugar levels, improves insulin resistance, and reduces the expression of cytokines. Salsalate can protect mice from metabolic disorders caused by high-fat diet and effectively improve the symptoms of type 2 diabetes, atherosclerosis and non-alcoholic steatohepatitis [2 ] .
    Salsalate
  • HY-161926
    YGT-31

    		PPAR Metabolic Disease
    YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .
    YGT-31
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)

    		GLP Receptor Metabolic Disease
    GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-17403
    Manidipine dihydrochloride

    CV-4093

    		 Calcium Channel NF-κB Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Manidipine dihydrochloride is a third-generation, lipophilic, orally active and highly vasoselective calcium channel antagonist (IC50 = 2.6 nM in guinea-pig ventricular cells) and acts as an antihypertensive agent. Manidipine effectively reduces blood pressure as well as improving insulin sensitivity, renal protection, and antiatherosclerotic activity. Manidipine also exerts anti-inflammatory activity mediated by NF-κB and antiviral activity against many flavivirus and negative-strand RNA viruses through the inhibition of calcium channel. Manidipine is widely applied to research of cardiovascular, metabolic disease and infection .
    Manidipine dihydrochloride
  • HY-139792
    Besigliptin tosylate

    SHR117887

    		 Others Metabolic Disease
    Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
    Besigliptin tosylate
  • HY-N0378
    D-Mannitol
    5+ Cited Publications

    Mannitol; Mannite

    		 Endogenous Metabolite Apoptosis Adrenergic Receptor PGC-1α PKA Metabolic Disease Cancer
    D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells .
    D-Mannitol
  • HY-168168
    (5aS,6R,6aR)-MK-8666

    		Others Metabolic Disease
    (5aS,6R,6aR)-MK-8666 is a selective GPR40 agonist with activity in promoting fatty acid-induced insulin secretion in pancreatic β cells and intestinal enteroendocrine cells. (5aS,6R,6aR)-MK-8666 has been studied for the inhibition of type 2 diabetes and has shown significant blood glucose lowering effects. Although (5aS,6R,6aR)-MK-8666 is considered to have potential inhibitory advantages, its development was stopped in Phase I clinical trials due to liver safety issues .
    (5aS,6R,6aR)-MK-8666
  • HY-W010934
    3β,5α,6β-Trihydroxycholestane

    		Biochemical Assay Reagents Others
    3β,5α,6β-Trihydroxycholestane is a steroid that occurs naturally in the body and is also found in certain foods. It belongs to a class of compounds known as cholestanes, which are closely related to the better known cholesterol. This particular compound is formed from cholesterol through a series of enzymatic reactions in the liver and other organs. It has been studied for its potential health benefits, including its ability to reduce inflammation and oxidative stress in the body. Some research suggests that it may also play a role in regulating blood sugar levels and improving insulin sensitivity. Despite these potential benefits, 3β,5α,6β-Trihydroxycholestane is not widely used as a supplement or medicine due to its relatively low content, focus on natural resources and limited research. However, researchers continue to investigate its potential uses and effects on human health.
    3β,5α,6β-Trihydroxycholestane
  • HY-149254
    PTP1B/AKR1B1-IN-1

    		Phosphatase Aldose Reductase Metabolic Disease
    PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels .
    PTP1B/AKR1B1-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: